Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report

Hasnie, Ammar; Hasnie, Usman; Patel, Nirav; Aziz, Muhammad Usman; Xie, Min; Lloyd, Steven G.; Prabhu, Sumanth D.

doi:10.1186/s12872-021-02183-3

Cited by 29 publications

(31 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found around 25 studies that met our criteria. After excluding duplication, we finally included 14 published articles in our study, which consists of 40 case reports (Table 1) [1,[5][6][7][8][9][10][11][12][13][14][15][16][17] of myocarditis after receiving the COVID-19 vaccine.…”

Section: Eligibility Criteriamentioning

confidence: 99%

COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports

Chen¹,

Ikwuanusi²,

Bommu³

et al. 2022

Cureus

View full text Add to dashboard Cite

After the surging rise in the Coronavirus disease 2019 (COVID-19) pandemic, the Food and Drug Administration (FDA) approved emergency approval of vaccinations to prevent life-threatening complications of COVID-19 infection. These vaccines are BNT162b2, mRNA-1273. Later, the FDA also approved JNJ-78436735. COVID-19 vaccination does not have major side effects, but there are some concerning adverse events reported right after vaccination. Myocarditis is one of them. Based on our analysis of 40 case reports, we are presenting the epidemiology and clinical picture of myocarditis related to the COVID-19 vaccine.Based on our analysis, we found that the majority of cases were seen in males with 90% predominance, and these cases were seen in the age group of 29.13 years old (mean, SD of 14.39 years). In 65% of cases, patients took the BNT162b2 vaccine; 30% of cases were reported with the mRNA-1273 vaccine; and 5% of cases with JNJ-78436735. Of all the cases, 80% of them are reported after the second dose of the vaccine with either Moderna or Pfizer.The characteristics of COVID-19 vaccine-related myocarditis were analyzed in this study. We identified several findings, ranging from age, gender, type of vaccination, presentation of symptoms, and diagnosis modality. This depicts the picture of COVID-19 vaccine-related myocarditis and what physicians should expect when dealing with the disease. Our analysis showed that more cases were reported after receiving the BNT162b2 vaccine compared to mRNA-1273 and JNJ-78436735 vaccines. Further research needs to be conducted to analyze the underlying cause of this association.

show abstract

Section: Eligibility Criteriamentioning

confidence: 99%

COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports

Chen¹,

Ikwuanusi²,

Bommu³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…The cases are mild and temporarily exist but can cause severe effects on adolescents. Pleuritic chest pain, dyspnoea, or palpitations are the symptoms that can be noticed especially in younger children with myocarditis besides, epigastric pain, profuse sweating, tachycardia, hypotension can also be observed in some cases (Albert et al 2021;Hasnie et al 2021;Maron et al 2021;McLean and Johnson 2021;Patrignani et al 2021;Snapiri et al 2021;Vogel 2021). According to multiple case reports, most of the symptoms for myocarditis arise within 1-4 days after the first or second dose vaccination of BNT162b2 or mRNA-1273.…”

Section: Myocarditis/perimyocarditismentioning

confidence: 99%

“…Cardiac magnetic resonance imaging was an effective tool for the diagnosis of myocarditis. Elevated troponin level was reported in almost every case; in some cases, creative protein and creatine kinase, CK-MB, and B-type natriuretic peptide levels were also reported higher (Albert et al 2021;Hasnie et al 2021;Maron et al 2021;McLean and Johnson 2021;Patrignani et al 2021;Snapiri et al 2021). Different drugs were introduced to treat and elevate the symptoms of myocarditis.…”

Section: Myocarditis/perimyocarditismentioning

confidence: 99%

“…Different drugs were introduced to treat and elevate the symptoms of myocarditis. Aspirin, colchicine, ibuprofen, beta-blockers, steroids or corticosteroids, intravenous anti-inflammatory drugs were used for the recovery of patients (Albert et al 2021;Hasnie et al 2021;Maron et al 2021;McLean and Johnson 2021;Patrignani et al 2021;Vogel 2021).…”

Section: Myocarditis/perimyocarditismentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review

Simnani

Singh

Kaur³

2021

3 Biotech

View full text Add to dashboard Cite

The COVID-19 pandemic has endangered world health and the economy. As the number of cases is increasing, different companies have started developing potential vaccines using both traditional and nano-based platforms to overcome the pandemic. Several countries have approved a few vaccine candidates for emergency use authorization (EUA), showing significant effectiveness and inducing a robust immune response. Oxford-AstraZeneca, Pfizer-BioNTech’s BNT162, Moderna’s mRNA-1273, Sinovac’s CoronaVac, Johnson & Johnson, Sputnik-V, and Sinopharm’s vaccine candidates are leading the race. However, the SARS-CoV-2 is constantly mutating, making the vaccines less effective, possibly by escaping immune response for some variants. Besides, some EUA vaccines have been reported to induce rare side effects such as blood clots, cardiac injury, anaphylaxis, and some neurological effects. Although the COVID-19 vaccine candidates promise to overcome the pandemic, a more significant and clear understanding is needed. In this review, we brief about the clinical trial of some leading candidates, their effectiveness, and their neutralizing effect on SARS-CoV-2 variants. Further, we have discussed the rare side effects, different traditional and nano-based platforms to understand the scope of future development.

show abstract

“…Meanwhile, numerous potentially toxic and expensive repurposed drugs have been espoused or used as clinical treatments, e.g., colchicine [19], glucocorticoids [20], remdesivir [14,21], and many others [22][23][24][25]. Although of significant value, even the currently available vaccines are not without occasional serious side effects [26][27][28]. Moreover, the efficacy of the vaccines has decreased as the virus has mutated [29,30].…”

Section: Introductionmentioning

confidence: 99%

Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection

Reíter

Sharma

Šimko

et al. 2022

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efficacy in preventing or treating this serious condition and all have side effects to differing degrees. We encourage the continued consideration of the use of the antioxidant and anti-inflammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientific publications have identified melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral effects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous different viruses, including three different coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most effective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profile over a wide range of doses and lacks significant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially beneficial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2.

show abstract

Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report

Cited by 29 publications

References 15 publications

COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports

COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports

COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review

Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection

Contact Info

Product

Resources

About